title: Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
authors.forename: Laurence
authors.initials: L
authors.lastname: Legros
authors.forename: Philippe
authors.initials: P
authors.lastname: Rousselot
authors.forename: Stéphane
authors.initials: S
authors.lastname: Giraudier
authors.forename: Michel
authors.initials: M
authors.lastname: Tulliez
authors.forename: Françoise
authors.initials: F
authors.lastname: Huguet
authors.forename: Franck-Emmanuel
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Francois-Xavier
authors.initials: FX
authors.lastname: Mahon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D004334:Drug Administration Schedule; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl